Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation
Background: Experimental studies revealed pro-inflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin, in patients with essential...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699528038416384 |
|---|---|
| author | Danilo Fliser Konrad Buchholz Hermann Haller |
| author_facet | Danilo Fliser Konrad Buchholz Hermann Haller |
| author_sort | Danilo Fliser |
| collection | DOAJ |
| description | Background: Experimental studies revealed pro-inflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin, in patients with essential hypertension and microinflammation. Methods and results: We measured a panel of vascular inflammation markers, including high-sensitivity C-reactive protein (hsCRP), and lipid levels during 12 weeks of therapy with olmesartan (n=100) or placebo (n=99) in a prospective double-blind multicenter study. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Blood pressure (BP) control was achieved with addition of hydrochlorothiazide. Olmesartan treatment had already significantly reduced serum levels of hsCRP (-15,1%; p<0,05), high-sensitivity tumor necrosis factor-alpha, hsTNF-alpha (-8,9%; p<0,02), interleukin-6, IL-6 (-14,0%; p<0,05), and monocyte chemotactic protein-1, MCP-1 (-6,5%; p<0,01) after 6 weeks of therapy, whereas placebo treatment (ie, BP reduction) had no major effect on inflammation markers. After 12 weeks of therapy, hsCRP (-21,1%; p<0,02), hsTNF-alpha (-13,6%; p<0,01), and IL-6 (-18,0%; p<0,01) decreased further with olmesartan and pravastatin co-therapy, but treatment with pravastatin alone (ie, co-therapy with placebo) did not significantly alter inflammation markers. In contrast, addition of pravastatin led to a significant (p<0,001) reduction in LDL cholesterol serum concentrations in the olmesartan and placebo treatment groups (-15,1% and -12,1%, respectively). Conclusions: Angiotensin II receptor blockade significantly reduces vascular microinflammation in patients with essential hypertension by as early as week 6 of therapy. This anti-inflammatory action of angiotensin II receptor antagonists may contribute to their beneficial cardiovascular effects. |
| format | Article |
| id | doaj-art-71729588191b4a669addbe429da5da1b |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 1970-01-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-71729588191b4a669addbe429da5da1b2025-08-20T03:18:34Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-019714201866Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationDanilo Fliser0Konrad Buchholz1Hermann Haller2Medical School Hannover, HannoverMedical School Hannover, HannoverMedical School Hannover, HannoverBackground: Experimental studies revealed pro-inflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin, in patients with essential hypertension and microinflammation. Methods and results: We measured a panel of vascular inflammation markers, including high-sensitivity C-reactive protein (hsCRP), and lipid levels during 12 weeks of therapy with olmesartan (n=100) or placebo (n=99) in a prospective double-blind multicenter study. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Blood pressure (BP) control was achieved with addition of hydrochlorothiazide. Olmesartan treatment had already significantly reduced serum levels of hsCRP (-15,1%; p<0,05), high-sensitivity tumor necrosis factor-alpha, hsTNF-alpha (-8,9%; p<0,02), interleukin-6, IL-6 (-14,0%; p<0,05), and monocyte chemotactic protein-1, MCP-1 (-6,5%; p<0,01) after 6 weeks of therapy, whereas placebo treatment (ie, BP reduction) had no major effect on inflammation markers. After 12 weeks of therapy, hsCRP (-21,1%; p<0,02), hsTNF-alpha (-13,6%; p<0,01), and IL-6 (-18,0%; p<0,01) decreased further with olmesartan and pravastatin co-therapy, but treatment with pravastatin alone (ie, co-therapy with placebo) did not significantly alter inflammation markers. In contrast, addition of pravastatin led to a significant (p<0,001) reduction in LDL cholesterol serum concentrations in the olmesartan and placebo treatment groups (-15,1% and -12,1%, respectively). Conclusions: Angiotensin II receptor blockade significantly reduces vascular microinflammation in patients with essential hypertension by as early as week 6 of therapy. This anti-inflammatory action of angiotensin II receptor antagonists may contribute to their beneficial cardiovascular effects.https://cardiovascular.elpub.ru/jour/article/view/2157angiotensinatherosclerosischolesterolhypertensioninflammation |
| spellingShingle | Danilo Fliser Konrad Buchholz Hermann Haller Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation Кардиоваскулярная терапия и профилактика angiotensin atherosclerosis cholesterol hypertension inflammation |
| title | Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation |
| title_full | Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation |
| title_fullStr | Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation |
| title_full_unstemmed | Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation |
| title_short | Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation |
| title_sort | anti inflammatory effects of angiotensin ii subtype 1 receptor blockade in hypertensive patients with microinflammation |
| topic | angiotensin atherosclerosis cholesterol hypertension inflammation |
| url | https://cardiovascular.elpub.ru/jour/article/view/2157 |
| work_keys_str_mv | AT danilofliser antiinflammatoryeffectsofangiotensiniisubtype1receptorblockadeinhypertensivepatientswithmicroinflammation AT konradbuchholz antiinflammatoryeffectsofangiotensiniisubtype1receptorblockadeinhypertensivepatientswithmicroinflammation AT hermannhaller antiinflammatoryeffectsofangiotensiniisubtype1receptorblockadeinhypertensivepatientswithmicroinflammation |